Treatment of depression in patients with congestive heart failure

Heart Failure Reviews

Volumn 14, Issue 1, 2009, Pages 7-12

  Shapiro, Peter A ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Antidepressants; Depression; Heart failure; Psychotherapy; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD PRESSURE; BLURRED VISION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE REHABILITATION; COGNITIVE THERAPY; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; HEART CONDUCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART OUTPUT; HEART PROTECTION; HEART RATE; HEART RATE VARIABILITY; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOSTILITY; HUMAN; HYPERTENSIVE CRISIS; LIVER FAILURE; LIVER TOXICITY; NONHUMAN; NORADRENALIN BLOOD LEVEL; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PSYCHOTHERAPY; QT INTERVAL; RISK REDUCTION; SEDATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; DEPRESSION; HEART FAILURE; HUMANS; PSYCHOTHERAPY; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 58149104438     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-007-9058-6     Document Type: Article

References (44)

1. Rosamond W, Flegal K, Friday G et al (2007) Heart disease and stroke statistics-2007 update: A report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 115, e69-171
2. Koenig HG (1998) Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 20:29-43
3. Jiang W, Alexander J, Christopher E et al (2001) Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 161:1849-1856
4. Rumsfeld JS, Havranek E, Masoudi FA et al (2003) Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 42:1811-1817
5. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA (2003) Depressive symptoms and health-related quality of life: The heart and soul study. JAMA 290(2):215-221
6. Faris R, Purcell H, Henein MY, Coats AJS (2002) Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. Eur J Heart Fail 4(4):541-551
7. Freedland KE, Carney RM, Davila-Roman VG, Rich MW, Skala JA, Jaffe AS. (1998) Major depression and survival in congestive heart failure. Psychosom Med 60:118
8. Roose SP, Glassman AH (1989) Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry 50:S1-18
9. Roose SP, Glassman AH, Dalack GW (1989) Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry 50:12-16
10. Roose SP, Glassman AH, Giardina EGV et al (1986) Nortriptyline in depressed patients with left ventricular impairment. JAMA 256:3253-3257
11. CAST Investigators (1989) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412
12. Echt DS, Liebson PR, Mitchelle LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 324:781-788
13. CAST II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227-233
14. Morganroth J, Goin JE (1991) Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. Circulation 84:1977-1983
15. Glassman AH, Roose SP, Bigger JT Jr (1993) The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 269:2673-2675
16. Sheline YI, Freedland KE, Carney RM (1997) How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 102(1):54-59
17. Shapiro PA (2004) Heart disease. In: Levenson JL (ed) APPI textbook of psychosomatic medicine. APPI, Washington, D.C., pp 423-444
18. Roose SP, Glassman AH, Attia E, Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151:1735-1739
19. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EGV, Bigger JT (1998) Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155:660-665
20. Roose SP, Laghrissi-Thode F, Kennedy JS et al (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287-291
21. Strik JJMH, Honig A, Lousberg R et al (2000) Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: Findings from a double-blind, placebo-controlled trial. Psychosom Med 62(6):783-789
22. Glassman AH, O'Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701-709
23. Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR. (2006) Onset of major depression associated with acute coronary syndromes. Relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry 63:283-288
24. Lesperance F, Frasure-Smith N, Koszycki D et al (2007) Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA 297(4):367-379
25. Musselman DL, Tomer A, Manatunga AK et al (1996) Exaggerated platelet reactivity in major depression. Am J Psychiatry 153:1313-1317
26. Laghrissi-Thode F, Wagner WR, Pollack BG, Johnson PC, Finkel MS. (1997) Elevated platelet factor 4 and beta-thromboglogulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 42:290-295
27. Pollock BG, Laghrissi-Thode F, Wagner WR (2000) Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 20(2):137-140
28. Serebruany VL, Glassman AH, Malinin AI et al (2003) Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 5:517-521
29. Serebruany VL, Glassman AH, Malinin AI et al (2003) Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy. Circulation 108(8):939-944
30. http://www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Serzone_PI.pdf. Accessed June 2, 2007
31. Lesperance F, Frasure-Smith N, Laliberte MA et al (2003) An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry 48:695-701
32. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV (1991) Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 148:512-516
33. Qin F, Shite J, Mao W, Liang C-S (2003) Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: Association with improvement of cardiac function. Eur J Pharmacol 461(2-3):149-158
34. Nissen SE (2006) ADHD drugs and cardiovascular risk. New Engl J Med 354:1445-1448
35. Wilens TE, Hammerness PG, Biederman J et al (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 66(2):253-259
36. Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF III (2006) Methylphenidate-enhanced antidepressant response to citalopram in the elderly: A double-blind, placebo-controlled pilot trial. Am J Geriat Psychiatry 14(2):181-185
37. Writing Committee for the ENRICHD Investigators (2003) Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 289(23):3106-3116
38. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES (1984) Interpersonal psychotherapy of depression. Basic Books, New York
39. Solimene MC (2007) Electroconvulsive therapy and the heart. Int J Cardiol 114(1):103
40. Zielinski RJ, Roose SP, Devanand DP, Woodring S, Sackeim H (1993) Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 150:904-909
41. Magid M, Lapid MI, Sampson SM, Mueller PS (2005) Use of electroconvulsive therapy in a patient 10 days after myocardial infarction. J ECT 21(3):182-185
42. Nuttall GA, Bowersox MR, Douglass SB et al (2004) Morbidity and mortality in the use of electroconvulsive therapy. J ECT 20(4):237-241
43. Dolenc TJ, Barnes RD, Hayes DL, Rasmussen KG (2004) Electroconvulsive therapy in patients with cardiac pacemakers and implantable cardioverter defibrillators. Pacing Clin Electrophysiol 27(9):1257-1263
44. Rayburn BK. (1997) Electroconvulsive therapy in patients with heart failure or valvular heart disease. Convuls Ther 13(3):145-156